|Canaccord Medical Technology & Diagnostics Forum December 4, 2012 at 9:00 a.m. ET Le Parker Meridien - New York City|
|Oppenheimer’s 23rd Annual Healthcare Conference December 12 & 13, 2012, corporate presentation on December 13, 2012 at 9:25 a.m. ET Waldorf Astoria - New York City|
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J. Quilty, the Company’s chief executive officer, will present a corporate overview and update at two conferences in December. They are:
To listen and view the presentations investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com. Archived copies of the presentations will also be available on Derma Sciences’ website. About Derma Sciences, Inc. Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for the healing of diabetic foot ulcers, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™, a gold-standard treatment for diabetic foot ulcers.